Description of Medical ServiceALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Description of Medical ConditionALK-positive advanced NSCLC.
Reason for Application-
Medical Service Type-
Previous Application Number1250
PICO Confirmation28 May 2012 – 5 July 2012
Consultation Protocol (PDF 250 KB)
Consultation Protocol (Word 740 KB)
Final Protocol (PDF 585 KB)
Final Protocol (Word 6128 KB)
Public Summary DocumentPublic Summary Document - November 2014 Update (PDF 273 KB)
Public Summary Document - November 2014 Update (Word 111 KB)
Meetings for this Application
ESC12 to 13 June 2014
MSAC3 October 2014
26 to 28 November 2014